These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 37306759)

  • 1. Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma.
    Rohila D; Park IH; Pham TV; Weitz J; Hurtado de Mendoza T; Madheswaran S; Ishfaq M; Beaman C; Tapia E; Sun S; Patel J; Tamayo P; Lowy AM; Joshi S
    Cancer Res; 2023 Aug; 83(16):2675-2689. PubMed ID: 37306759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer.
    Li TJ; Jin KZ; Li H; Ye LY; Li PC; Jiang B; Lin X; Liao ZY; Zhang HR; Shi SM; Lin MX; Fei QL; Xiao ZW; Xu HX; Liu L; Yu XJ; Wu WD
    Cancer Lett; 2022 Apr; 530():142-155. PubMed ID: 35077803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting macrophage Syk enhances responses to immune checkpoint blockade and radiotherapy in high-risk neuroblastoma.
    Rohila D; Park IH; Pham TV; Jones R; Tapia E; Liu KX; Tamayo P; Yu A; Sharabi AB; Joshi S
    Front Immunol; 2023; 14():1148317. PubMed ID: 37350973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
    Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-β1/Gfi-1 axis.
    Xian G; Zhao J; Qin C; Zhang Z; Lin Y; Su Z
    Cancer Lett; 2017 Jan; 385():65-74. PubMed ID: 27840243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages.
    Beatty GL; Winograd R; Evans RA; Long KB; Luque SL; Lee JW; Clendenin C; Gladney WL; Knoblock DM; Guirnalda PD; Vonderheide RH
    Gastroenterology; 2015 Jul; 149(1):201-10. PubMed ID: 25888329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
    Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
    Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFNα-induced BST2
    Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
    Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of TGF-β in pancreatic ductal adenocarcinoma progression and PD-L1 expression.
    Hussain SM; Kansal RG; Alvarez MA; Hollingsworth TJ; Elahi A; Miranda-Carboni G; Hendrick LE; Pingili AK; Albritton LM; Dickson PV; Deneve JL; Yakoub D; Hayes DN; Kurosu M; Shibata D; Makowski L; Glazer ES
    Cell Oncol (Dordr); 2021 Jun; 44(3):673-687. PubMed ID: 33694102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis.
    Ho TTB; Nasti A; Seki A; Komura T; Inui H; Kozaka T; Kitamura Y; Shiba K; Yamashita T; Yamashita T; Mizukoshi E; Kawaguchi K; Wada T; Honda M; Kaneko S; Sakai Y
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33188035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression.
    Kaneda MM; Cappello P; Nguyen AV; Ralainirina N; Hardamon CR; Foubert P; Schmid MC; Sun P; Mose E; Bouvet M; Lowy AM; Valasek MA; Sasik R; Novelli F; Hirsch E; Varner JA
    Cancer Discov; 2016 Aug; 6(8):870-85. PubMed ID: 27179037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models.
    Sakai Y; Miyazawa M; Komura T; Yamada T; Nasti A; Yoshida K; Takabatake H; Yamato M; Yamashita T; Yamashita T; Mizukoshi E; Okuzono M; Ho TTB; Kawaguchi K; Wada T; Honda M; Kaneko S
    Cancer Sci; 2019 Mar; 110(3):903-912. PubMed ID: 30657234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic Stellate Cells Promote Tumor Progression by Promoting an Immunosuppressive Microenvironment in Murine Models of Pancreatic Cancer.
    Li C; Cui L; Yang L; Wang B; Zhuo Y; Zhang L; Wang X; Zhang Q; Zhang S
    Pancreas; 2020 Jan; 49(1):120-127. PubMed ID: 31856087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
    Zhu Y; Knolhoff BL; Meyer MA; Nywening TM; West BL; Luo J; Wang-Gillam A; Goedegebuure SP; Linehan DC; DeNardo DG
    Cancer Res; 2014 Sep; 74(18):5057-69. PubMed ID: 25082815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization.
    Chandrakesan P; Panneerselvam J; May R; Weygant N; Qu D; Berry WR; Pitts K; Stanger BZ; Rao CV; Bronze MS; Houchen CW
    Mol Cancer Ther; 2020 Jul; 19(7):1539-1549. PubMed ID: 32371580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma.
    Fitzgerald AA; Wang S; Agarwal V; Marcisak EF; Zuo A; Jablonski SA; Loth M; Fertig EJ; MacDougall J; Zhukovsky E; Trivedi S; Bhatia D; O'Neill V; Weiner LM
    J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34737215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IGFBP2 promotes tumor progression by inducing alternative polarization of macrophages in pancreatic ductal adenocarcinoma through the STAT3 pathway.
    Sun L; Zhang X; Song Q; Liu L; Forbes E; Tian W; Zhang Z; Kang Y; Wang H; Fleming JB; Pasche BC; Zhang W
    Cancer Lett; 2021 Mar; 500():132-146. PubMed ID: 33309859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages.
    Chen Q; Wang J; Zhang Q; Zhang J; Lou Y; Yang J; Chen Y; Wei T; Zhang J; Fu Q; Ye M; Zhang X; Dang X; Liang T; Bai X
    Br J Cancer; 2019 Oct; 121(9):786-795. PubMed ID: 31588122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
    D'Errico G; Alonso-Nocelo M; Vallespinos M; Hermann PC; Alcalá S; García CP; Martin-Hijano L; Valle S; Earl J; Cassiano C; Lombardia L; Feliu J; Monti MC; Seufferlein T; García-Bermejo L; Martinelli P; Carrato A; Sainz B
    Oncogene; 2019 Jul; 38(27):5469-5485. PubMed ID: 30936462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancreatic Ductal Adenocarcinoma.
    Lewis CS; Backman C; Ahsan S; Cliff A; Hariharan A; Yeh JJ; Zhang X; Xie C; Sohal DPS; Bogdanov VY
    Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.